Limitations of Prostate-specific Antigen Testing After a Prostate Cancer Diagnosis

Megan E V Caram; Ted A Skolarus; Kathleen A Cooney

doi:10.1016/j.eururo.2015.12.045

Limitations of Prostate-specific Antigen Testing After a Prostate Cancer Diagnosis

Eur Urol. 2016 Aug;70(2):209-10. doi: 10.1016/j.eururo.2015.12.045. Epub 2016 Jan 15.

Authors

Megan E V Caram¹, Ted A Skolarus², Kathleen A Cooney³

Affiliations

¹ Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI, USA; Health Services Research and Development Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA. Electronic address: mveresh@med.umich.edu.
² Health Services Research and Development Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
³ Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI, USA; Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.

PMID: 26776937
DOI: 10.1016/j.eururo.2015.12.045

Abstract

Prostate-specific antigen (PSA) is frequently used in isolation to guide treatment decisions in men with recurrent prostate cancer, a practice discouraged by prostate cancer working groups and guidelines. Instead, PSA should be used with imaging and other factors to make treatment decisions.

Published by Elsevier B.V.

Publication types

Editorial

MeSH terms

Clinical Decision-Making
Humans
Male
Patient Care Management / organization & administration
Prostate-Specific Antigen / analysis*
Prostatic Neoplasms* / diagnosis
Prostatic Neoplasms* / therapy

Substances

Prostate-Specific Antigen

Grants and funding

IK2 HX001162/HX/HSRD VA/United States